The drug facts box: Improving the communication of prescription drug information

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue SUPPL. 3, 2013, Pages 14069-14074

  Schwartz, Lisa M ^a   Woloshin, Steven ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Data presentation; Evidence summaries; Physician patient communication

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; CONSUMER; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRIORITY JOURNAL; PUBLIC HEALTH; DATA PRESENTATION; EVIDENCE SUMMARIES; INFORMATION DISSEMINATION; INTERPERSONAL COMMUNICATION; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT EDUCATION; PHYSICIAN-PATIENT COMMUNICATION; SCIENCE; STATISTICS;

DATA PRESENTATION; EVIDENCE SUMMARIES; PHYSICIAN-PATIENT COMMUNICATION;

COMMUNICATION; DRUG APPROVAL; DRUG LABELING; HUMANS; INFORMATION DISSEMINATION; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT EDUCATION AS TOPIC; PRESCRIPTION DRUGS; SCIENCE;

EID: 84887799096     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1214646110     Document Type: Article

References (49)

1. National Center for Health Statistics (2012) Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Table 99 (National Center for Health Statistics, Hyattsville, MD).
2. Federal Food, Drug, and Cosmetic Act, 3 Fed. Reg. 3168 (Dec. 28, 1938).
3. Bell RA, Kravitz RL, Wilkes MS (1999) Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med 14(11):651-657.
4. Bell RA, Wilkes MS, Kravitz RL (2000) The educational value of consumer-targeted prescription drug print advertising. J Fam Pract 49(12):1092-1098. (Pubitemid 32003442)
5. Hoffman JR, Wilkes M (1999) Direct to consumer advertising of prescription drugs. An idea whose time should not come. BMJ 318(7194):1301-1302. (Pubitemid 29219039)
6. Hollon MF (1999) Direct-to-consumer marketing of prescription drugs: Creating consumer demand. JAMA 281(4):382-384.
7. Holmer AF (1999) Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA 281(4):380-382.
8. Kravitz RL, et al. (2005) Influence of patients' requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. JAMA 293(16):1995-2002. (Pubitemid 40570893)
9. Spending review (2012) DTC Perspectives, p. 12. Available at www.dtcperspectives.com/images/email/DTCPM-Spring2012.pdf. Accessed June 9, 2013.
10. US Food and Drug Adminstration (2011) FY2011 Congressional budget request. Available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/ Reports/BudgetReports/UCM202321.pdf. Accessed August 22, 2012.
11. Brownfield ED, Bernhardt JM, Phan JL, Williams MV, Parker RM (2004) Direct-to-consumer drug advertisements on network television: An exploration of quantity, frequency, and placement. J Health Commun 9(6):491-497. (Pubitemid 40115878)
12. IMS Institute for Healthcare Informatics (2012) The use of medicines in the United States: Review of 2011. Available at www.imshealth.com/ims/Global/ Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/ IHII-Medicines-in-U.S-Report-2011.pdf. Accessed June 9, 2013.
13. Woloshin S, Schwartz L, Tremmel J, Welch H (2001) Direct to consumer drug advertisements: What are Americans being sold? Lancet 358:1141-1146. (Pubitemid 32971847)
14. Forrow L, Taylor WC, Arnold RM (1992) Absolutely relative: How research results are summarized can affect treatment decisions. Am J Med 92(2):121-124.
15. Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM (1993) The framing effect of relative and absolute risk. J Gen Intern Med 8(10):543-548. (Pubitemid 23312931)
16. Naylor CD, Chen E, Strauss B (1992) Measured enthusiasm: Does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 117(11):916-921.
17. US Food and Drug Administration. Medication guides. Available at http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm. Accessed August 10, 2012.
18. US Food and Drug Administration. Drugs@FDA. Abilify medication guide. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085804.pdf. DrugDetails. Accessed August 22, 2012.
19. US Food and Drug Administration. An introduction to the improved FDA prescription drug labeling. Available at http://www.fda.gov/downloads/Training/ ForHealthProfessionals/UCM090796.pdf. Accessed August 22, 2012.
20. Schwartz LM, Woloshin S (2009) Lost in transmission - FDA drug information that never reaches clinicians. N Engl J Med 361(18):1717-1720.
21. Schwartz LM, Woloshin S (2012) How the FDA forgot the evidence: The case of donepezil 23 mg. BMJ 344:e1086.
22. U.S. Food and Drug Administration. (2005) Drugs@FDA. Approval History NDA 021782 Rozerem. Medical review. Available at:http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2005/021782s000-Rozerem-medr.pdf. Accessed November 26, 2012.
23. U.S. Food and Drug Administration. Drugs@FDA. Abilify label. Available at www. accessdata.fda.gov/drugsatfda-docs/label/2012/021436s034,021713s025, 021729s018,021866s020lbl.pdf. Accessed June 9, 2013.
24. U.S. Food and Drug Administration. (2006) Clinical studies section of labeling for human prescription drug and biological products: Content and format. Available at http://www.fda.gov/RegulatoryInformation/Guidances/ ucm127509.htm. Accessed November 26, 2012.
25. Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with fi ndings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. PLoS Med 4(6):e184.
26. Dwan K, et al. (2008) Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 3(8):e3081.
27. Ridker PM, Torres J (2006) Reported outcomes in major cardiovascular clinical trials funded by for-pro fi t and not-for-profi t organizations: 2000-2005. JAMA 295(19):2270-2274. (Pubitemid 43736577)
28. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its infl uence on apparent efficacy. N Engl J Med 358(3):252-260.
29. Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) Narrative review: The promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145(4):284-293. (Pubitemid 46768613)
30. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA 291(20):2457-2465. (Pubitemid 38669189)
31. Vedula SS, Bero L, Scherer RW, Dickersin K (2009) Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 361(20):1963-1971.
32. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL (2003) Association of funding and conclusions in randomized drug trials: A refl ection of treatment effect or adverse events? JAMA 290(7):921-928. (Pubitemid 37430464)
33. Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsigni ficant results for primary outcomes. JAMA 303(20):2058-2064.
34. Yank V, Rennie D, Bero LA (2007) Financial ties and concordance between results and conclusions in meta-analyses: Retrospective cohort study. BMJ 335(7631):1202-1205. (Pubitemid 350273305)
35. Golder S, Loke YK (2008) Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol 66(6):767-773.
36. Berman RM, et al. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68(6):843-853. (Pubitemid 47015482)
37. Marcus RN, et al. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28(2):156-165. (Pubitemid 351417120)
38. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: Publishing and editorial issues related to publication in biomedical journals: Obligation to register clinical trials. Available at http://www.icmje.org/publishing-10register.html. Accessed November 26, 2012.
39. International Committee of Medical Journal Editors (2007) Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. Available at http://www.icmje.org/2007-urm. pdf. Accessed November 26, 2012.
40. CONSORT. The CONSORT statement. (2012) Available at http://www.consort- statement.org/consort-statement/. Accessed November 26, 2012.
41. US Food and Drug Administration. (2007) Drugs@FDA. Drug approval package. NDA 021436s018. Abilify. Available at http://www.accessdata.fda.gov/Scripts/ cder/DrugsatFDA/index.cfm?fuseaction=Search.Label-ApprovalHistory#apphistt. Accessed August 22, 2012.
42. Schwartz LM, Woloshin S, Welch HG (2007) The drug facts box: Providing consumers with simple tabular data on drug benefit and harm. Med Decis Making 27(5):655-662. (Pubitemid 47547602)
43. Schwartz LM, Woloshin S (2011) Communicating uncertainties about prescription drugs to the public: A national randomized trial. Arch Intern Med 171(16):1463-1468.
44. Schwartz LM, Woloshin S, Welch HG (2009) Using a drug facts box to communicate drug benefits and harms: Two randomized trials. Ann Intern Med 150(8):516-527.
45. Woloshin S, Schwartz L, Welch H (2004) The value of bene fi t data in direct-to-consumer drug ads. Health Aff, 10.1377/hlthaff.w4.234.
46. Woloshin S, Schwartz LM (2011) Communicating data about the benefits and harms of treatment: A randomized trial. Ann Intern Med 155(2):87-96.
47. US Food and Drug Administration (2009) Minutes of the risk communication advisory committee. Available at http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ RiskCommunicationAdvisoryCommittee/UCM152593.pdf. Accessed June 10, 2013.
48. Patient Protection and Affordable Care Act. Pub. L, No. 111-148, Section 3507 (Mar. 23, 2010).
49. Fischhoff B (2011) Communicating Risks and Benefits: An Evidence-Based User's Guide (US Food and Drug Administration, US Department of Health and Human Services).